Every 10-Q that Nuwellis Inc (NUWE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NUWE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUWE filings page.
Nuwellis, Inc. reported higher revenue but continued losses for the quarter and six months ended June 30, 2026. Net sales were $1.97 million for the quarter and $4.37 million for the first half, up 14.1% and 20.5% year over year, driven by strong console and circuit growth.
Gross profit rose to $3.18 million for the first half, with gross margin improving to 72.8% from 55.8%, mainly from contract manufacturing. However, the company posted a six‑month net loss of $9.37 million, with operating expenses increasing, particularly in selling, general and administrative and research and development.
Cash, cash equivalents and restricted cash totaled $4.03 million at June 30, 2026. Operations used $6.29 million of cash in the first half, offset by $9.42 million of financing inflows, including a June 2026 equity and warrant offering. Management states existing capital is expected to fund operations into the second quarter of 2027, yet recurring losses, an accumulated deficit of $325.7 million, and the need for additional capital raise substantial doubt about the company’s ability to continue as a going concern.
The company executed a 1‑for‑35 reverse stock split, issued new Series C and D warrants classified as liabilities, and later reclassified them to equity on a pro forma basis, resulting in pro forma stockholders’ equity of $4.39 million and ongoing compliance with Nasdaq’s minimum equity requirement. Two material weaknesses in internal control over financial reporting remain unresolved.
Nuwellis, Inc. reported higher first-quarter 2026 revenue but continued sizable losses and tight liquidity. Net sales for the three months ended March 31, 2026 rose to $2.4 million from $1.9 million, driven by a large increase in console sales and higher circuit usage, lifting gross margin to 70.1%.
The company posted a net loss of $4.5 million, wider than $3.0 million a year earlier, as selling, general and administrative expense grew to $4.5 million and research and development expense rose to $1.7 million, partly due to the Rendiatech asset acquisition and related in‑process R&D.
Cash, cash equivalents and restricted cash were $2.2 million as of March 31, 2026. Management states existing capital will fund operations only into the second quarter of 2026, and the filing indicates substantial doubt about Nuwellis’ ability to continue as a going concern without additional financing. During the quarter, the company raised roughly $5.0 million gross through a January 2026 private placement and warrant inducement transaction and issued 150,000 shares as part of the Rendiatech acquisition, which adds automated kidney function monitoring technology to its cardiorenal platform.
Nuwellis (NUWE) filed its Q3 2025 10‑Q. Net sales were $2.217 million, down from $2.367 million a year ago, as lower console pricing and reduced international activity offset a 15% increase in circuit sales. Gross margin was 65.2% versus 70.0% last year. The company reported quarterly net income of $468,000, aided by a $3.161 million non‑cash gain from the change in fair value of warrant liabilities.
Year‑to‑date, net sales were $5.846 million versus $6.418 million and net loss was $15.099 million. Operating cash flow for the nine months was an outflow of $7.780 million. Cash and cash equivalents were $3.094 million as of September 30, 2025. Management states that existing capital resources are expected to support operations into the first quarter of 2026, while acknowledging “substantial doubt” about the ability to continue as a going concern.
During the quarter, Nuwellis closed a June public offering with approximately $5.0 million in gross proceeds, executed a 1‑for‑42 reverse stock split effective July 3, 2025, and launched an ATM program, selling 447,288 shares for about $1.9 million in net proceeds by September 30. The company exited selected international operations (with about $254,000 accrued for related obligations), terminated the REVERSE‑HF clinical trial (anticipated savings of approximately $4.0 million over 2.5 years), and transitioned manufacturing to KDI to streamline operations.